DIANA SMITH: Open Payments
NPI 1396121497 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$804 in 45 payments from 12 companies in 2025. Trend: 2023 $817 · 2024 $668 · 2025 $804
Food & beverage: $804
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $171 |
| Novartis Pharmaceuticals Corporation | 6 | $153 |
| Novo Nordisk Inc | 15 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $118 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $65 |
| PFIZER INC. | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| SANOFI PASTEUR INC. | 1 | $17 |
| Exact Sciences Corporation | 1 | $16 |
Products named: CUVITRU, Ozempic, Rhapsido, AIRSUPRA, Kerendia, Rybelsus, BREZTRI, FARXIGA.
Industry payments across AL — which companies pay providers there.
